ProCol vascular bioprosthesis for vascular access: midterm results

Area of Science:

• Vascular Surgery
• Biomaterials Science
• Nephrology

Background:

• Vascular access (VA) is crucial for hemodialysis (HD).
• Patients often present with prior failed autologous access sites, necessitating alternative materials.
• Evaluating novel biomaterials for durable and safe VA is essential.

Purpose of the Study:

• To assess the safety and efficacy of ProCol vascular bioprostheses for VA.
• To investigate ProCol's performance in patients with a history of failed access.
• To determine the patency rates and complication profile of ProCol grafts.

Main Methods:

• A prospective study involving 24 hemodialysis patients.
• Placement of 25 arteriovenous (AV) bovine vein grafts (ProCol bioprostheses).
• All patients had a history of failed autologous access sites.

Main Results:

• Successful graft placement in all patients with no immediate complications.
• Midterm follow-up (6-26 months) revealed primary patency rates of 90% (6 months), 80% (12 months), and 70% (24 months).
• Satisfactory graft characteristics for cannulation and hemostasis were observed.

Conclusions:

• ProCol vascular bioprosthesis is a promising material for vascular access.
• The bioprosthesis offers good midterm patency rates.
• Low complication rates suggest a favorable safety profile for hemodialysis patients.